The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...

Department of Biochemistry and Molecular Biology, Southern Illinois University School of Medicine, Carbondale, IL, United States Nucleoside reverse transcriptase inhibitors (NRTIs) were the first ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

Nucleoside reverse transcriptase inhibitor exposure is significantly associated with a reduced risk for subsequent development of Alzheimer disease, reinforcing the idea that inflammasome inhibition ...

Department of Medicinal Chemistry, Shandong Key Laboratory of Druggability Optimization and Evaluation for Lead Compounds, Key Laboratory of Chemical Biology (Ministry of Education), School of ...

Existing autoimmune drugs may prevent or reverse a serious side effect faced by patients with cancer. Immunotherapy-induced type 1 diabetes is a serious side effect faced by some patients receiving ...

The investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to placebo, with dose-proportional pharmacokinetics, among adults with a low ...

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

On Thursday, the FDA approved lenacapavir, to be sold as Yeztugo, for the prevention of HIV in the U.S. The below essay, adapted from “Breakthrough: The Quest for Life-Changing Medicine” by William ...